Table 1.

Combination therapies for gynecologic malignancies in recent clinical trials

CombinationIndicationTrial sizeTrial phasePrimary endpointTrial completion date
Atezolizumab + bevacizumab2L+PR, CRC, RCC, NSCLC, TNBC, gastricN = 240Phase I, safety expansion cohort 2L+PR ovarian added 7-2015DLTDec 2018
Vanucizumab + atezolizumab2L + AST incl. PR/Ref ovarianN = 132Phase IORRDec 2016
Atezolizumab ± bevacizumab ± aspirin vs. bevacizumab vs. atezolizumab2-4L PR ovarianN = 160Phase II/III6m PFSJan 2021
Pembrolizumab + ziv-aflibercept2-3L PRN = 36Phase IDLTDec 2018
Pembrolizumab + bevacizumab + Cyclophosphamide2L + ovarianN = 40Phase II/IIIPFSDec 2018
Nivolumab+ bevacizumab2-4L ovarianN = 38Phase II/IIIORRFeb 2020
Durvalumab + olaparib + cediranibASTN = 384Phase I/IIORRDec 2018
Olaparib + tremelimumab2L PR or PPSR ovarianN = 68Phase II/IIISafetySept 2019
Olaparib + tremelimumab2L + gBRCAm ovarianN = 50Phase II/IIIORRFeb 2020
Durvalumab+ tremelimumab+ olaparibPSR/PRR BRCAm ovarianN = 39Phase II/IIIPFSAug 2019
Pembrolizumab + niraparibTNBC, 3-5L (P1) or 3-4L (P2) PRR ovarianN = 121Phase II/IIIORRMay 2018
TSR-042 + niraparib or paclitaxel/carboplatin vs. TSR-042 + bevacizumab vs. TSR-042 + bevacizumab + paclitaxel/carboplatinASTN = 168Phase ISafetyOct 2019
BGB-290 + BGB-A317 (PD1)ASTN = 230Phase IORRApr 2019
Rucaparib + atezolizumabBRCAm/HRD+ PSR OC, TNBCN = 48Phase II/IIIDLTJan 2019
Rucaparib + nivolumab vs. Rucaparib vs. nivolumab vs. placebo1L mtx all-comersN = 1,012Phase II/IIIPFSDec 2024
Talazoparib + avelumabNSCLC, BC, PSR ovarian, bladder, prostateN = 316Phase II/IIIORRMar 2020
BMS-986016 (LAG3) ± nivolumabAST, ovarian cohort only in the dose escalation armN = 1,000Phase ISafetyAug 2020
Nivolumab + varlilumab (CD27)2-6L ovarian, NSCLC, mel, CRC, SCCHNN = 175Phase II/IIIORRDec 2018
Nivolumab vs. nivolumab + ipilimumab (CTLA-4)2-4L PR or PPSR ovarianN = 96Phase II/IIIORRDec 2020
FPA008 ± nivolumab (CSF1R)2L+ ovarian, NSCLC, SCLC, SCCHN, panc, RCC, GliomasN = 295Phase ISafety, ORRMar 2019
Nivolumab + IFN-gamma2L+ ASTN = 15Phase ISafetyDec 2019
nivolumab + WT1 (vaccine)2L + maintenance ovarianN = 11Phase IDLTApr 2019
ABBV-428 ± nivolumab (CD40)2L+ AST incl. ovarianN = 172Phase ISafetyApr 2019
Atezolizumab + GDC-0919 (IDO1)AST, ovarian cohort added in aug 206N = 158Phase IDLTDec 2019
Atezolizumab ± guadecitabline ± CDX-1401 vaccine (HMA)2L+ PRR ovarianN = 78Phase II/IIIPFSMar 2020
Avelumab + defactinib (FAK)4-7L ovarianN = 98Phase IORRNov 2018
Durvalumab + tremelimumab (CTLA-4)2L+ ovarian, RCC, CRC and cervicalN = 106Phase ISafetyJun 2019
Durvalumab + VTX-2337 (TLR8) + Pegylated Liposomal Doxorubicin2-3L PRR or PPSR ovarianN = 53Phase II/IIIPFSDec 2018
Durvalumab + AZD1775 (wee1)ASTN = 55Phase IDLTApr 2019
Durvalumab + tremelimumab + chemotherapy (CTLA-4)1L ASTN = 42Phase ISafetyJun 2019
Durvalumab + TPIV200 (vaccine)2L + PRR ovarianN = 29Phase II/IIIORRMay 2019
Durvalumab + tremelimumab (CTLA-4)PRR ovarianN = 100Phase II/IIIirPFSMay 2021
Durvalumab + trabectedin (DNA groove)gBRCAm ovarian/sarcomaN = 50Phase IMTDMay 2020
Durvalumab + ONCOS-102 (T-cell adenovirus)AST incl. PRR ovarianN = 78Phase II/IIISafetyJul 2020